0.9288
price up icon0.00%   0.00
 
loading
Schlusskurs vom Vortag:
$0.9288
Offen:
$0.9389
24-Stunden-Volumen:
559
Relative Volume:
33.03
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.01M
KGV:
-0.0109
EPS:
-85.4
Netto-Cashflow:
$-18.31M
1W Leistung:
-3.36%
1M Leistung:
-69.06%
6M Leistung:
-81.55%
1J Leistung:
-88.61%
1-Tages-Spanne:
Value
$0.9288
$0.9389
1-Wochen-Bereich:
Value
$0.9288
$0.9389
52-Wochen-Spanne:
Value
$0.9288
$0.9389

Vaccinex Inc Stock (VCNX) Company Profile

Name
Firmenname
Vaccinex Inc
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
VCNX's Discussions on Twitter

Vergleichen Sie VCNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VCNX
Vaccinex Inc
0.9288 0 0 -22.01M -18.31M -85.40
Biotechnology icon
ONC
Beigene Ltd Adr
240.41 25.57B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.10 111.79B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 39.90M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
591.85 65.28B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.93 6.31B 0 -153.72M -103.81M -2.00

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-09-23 Herabstufung BTIG Research Buy → Neutral
2018-09-04 Eingeleitet Ladenburg Thalmann Buy

Vaccinex Inc Aktie (VCNX) Neueste Nachrichten

pulisher
May 27, 2025

Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Vaccinex presents promising cancer treatment data at ASCO - Investing.com

May 27, 2025
pulisher
May 27, 2025

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting | VCNX Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Vaccinex to Report Promising New Clinical Results of - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan

May 27, 2025
pulisher
May 20, 2025

Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World

May 20, 2025
pulisher
May 13, 2025

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire

May 13, 2025
pulisher
Apr 25, 2025

Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World

Apr 25, 2025
pulisher
Apr 21, 2025

Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire

Apr 21, 2025
pulisher
Apr 15, 2025

VACCINEX, INC. SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 08, 2025

Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews

Apr 08, 2025
pulisher
Apr 03, 2025

Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail

Apr 03, 2025
pulisher
Apr 01, 2025

Vaccinex Delays Yearly Report Filing - TipRanks

Apr 01, 2025
pulisher
Mar 20, 2025

Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 19, 2025

Vaccinex director resigns, no disagreement cited - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Stocks in play: Neo Performance Materials Inc. - The Globe and Mail

Mar 18, 2025
pulisher
Mar 13, 2025

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Mar 13, 2025
pulisher
Mar 10, 2025

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance

Mar 10, 2025
pulisher
Mar 08, 2025

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire

Mar 08, 2025
pulisher
Mar 07, 2025

Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan

Mar 07, 2025
pulisher
Feb 28, 2025

Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga

Feb 28, 2025
pulisher
Feb 20, 2025

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World

Feb 20, 2025
pulisher
Feb 13, 2025

Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News

Feb 13, 2025
pulisher
Jan 22, 2025

RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News

Jan 22, 2025
pulisher
Jan 08, 2025

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World

Jan 08, 2025
pulisher
Dec 20, 2024

Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR

Dec 20, 2024
pulisher
Dec 19, 2024

Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com

Dec 19, 2024
pulisher
Dec 19, 2024

Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa

Dec 18, 2024
pulisher
Dec 18, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India

Dec 18, 2024
pulisher
Dec 17, 2024

Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India

Dec 17, 2024
pulisher
Dec 17, 2024

Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch

Dec 17, 2024
pulisher
Dec 17, 2024

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance

Dec 17, 2024
pulisher
Dec 17, 2024

Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com

Dec 17, 2024
pulisher
Dec 17, 2024

Vaccinex receives delisting notice from Nasdaq, shares down over 49% - MSN

Dec 17, 2024
pulisher
Dec 17, 2024

Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times

Dec 17, 2024

Finanzdaten der Vaccinex Inc-Aktie (VCNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$285.56
price down icon 1.56%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):